Arcutis Biotherapeutics, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. The company is a commercial-stage dermatology biopharmaceutical company with one reportable segment.
Business context and operating progress
- ZORYVE cream is marketed for plaque psoriasis in the U.S. and Canada; the U.S. indication expanded to patients aged 6 and older in October 2023.
- ZORYVE foam was approved in December 2023 for seborrheic dermatitis in patients aged 9 and older and launched in late January 2024. The filing reports approximately 7,000 prescriptions through February 16, 2024.
- Management reported approximately 165,000 cumulative ZORYVE cream prescriptions, more than 10,700 prescribers, and coverage available to an estimated 132 million commercially insured U.S. lives as of February 16, 2024. These are company-reported commercial indicators, not revenue figures.
- The pipeline includes ZORYVE cream for atopic dermatitis, ZORYVE foam for scalp and body psoriasis, ARQ-255 for alopecia areata, reformulated ARQ-252, and preclinical ARQ-234 for atopic dermatitis.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Product revenue, net | $29.2 million | $3.7 million |
| Other revenue | $30.4 million | — |
| Total revenue | $59.6 million | $3.7 million |
| Cost of sales | $5.0 million | $0.8 million |
| Research and development | $110.6 million | $182.4 million |
| Selling, general and administrative | $185.1 million | $122.1 million |
| Operating loss | $241.1 million | $301.6 million |
| Net loss | $262.1 million | $311.5 million |
| Net loss per share, basic and diluted | $3.78 | $5.66 |
| Cash used in operating activities | $247.1 million | $257.7 million |
- Product revenue rose $25.5 million year over year, which management attributed primarily to customer demand. The $30.0 million Huadong upfront license payment was recognized as revenue; the company received $27.0 million net of $3.0 million Chinese withholding tax.
- Approximate product gross profit was $24.2 million, or 82.9% of net product revenue, based on reported product revenue less cost of sales. Cost of sales includes royalties and intangible amortization; previously expensed pre-approval inventory also affects unit costs.
- R&D expense fell 39%, mainly reflecting completion of pivotal trials, the prior-year ARQ-234 in-process R&D charge, and manufacturing costs shifting to inventory. SG&A rose 52%, mainly due to commercial staffing, sales and marketing, and professional services.
- At year-end, cash and cash equivalents were $88.4 million, marketable securities $183.5 million, and restricted cash $0.9 million. Total cash, cash equivalents, restricted cash, and marketable securities were $272.8 million. Current assets were $330.4 million and current liabilities $46.7 million.
- Debt principal outstanding was $200.0 million; the balance-sheet carrying amount, net of debt costs and including accrued final fee, was $201.8 million. The floating interest rate was 12.90% at year-end. Undiscounted future principal and interest payments were $292.4 million, including $213.9 million due in 2027.
- Stockholders’ equity declined to $88.7 million from $209.6 million. Common shares issued increased to 96.8 million from 61.1 million, reflecting financing and other share issuances; 7.5 million pre-funded warrants remained unexercised at year-end.
Material changes and outlook
- The company expects continuing losses and significant commercial, development, and operating expenses. It states that existing capital resources are expected to cover at least 12 months from the financial-statement issuance date only if the debt is not accelerated.
- A November 2023 loan amendment requires at least $31.0 million of qualifying net cash proceeds by April 1, 2024. As of the filing, the company reported raising $5.3 million toward the requirement and was not yet in compliance. Failure to meet it would trigger an event of default and could permit acceleration of the debt.
- The auditor’s report includes a going-concern explanatory paragraph, citing recurring losses and the unmet financing covenant. The financial statements contain no adjustments for the possible outcome. Management’s stated ability to continue depends on avoiding debt acceleration and obtaining funding.
- Management anticipated an FDA decision on the atopic dermatitis sNDA for patients aged 6 and older by July 7, 2024, and planned to submit an sNDA for foam in scalp and body psoriasis in the second half of 2024. These are forward-looking plans, not assurances of approval.
- In August 2023, Huadong received an exclusive license for topical roflumilast in Greater China and Southeast Asia. Potential additional payments include up to $24.0 million in development and regulatory milestones, $40.3 million in sales milestones, and tiered royalties.
- On February 14, 2024, the company received a Paragraph IV notice concerning Padagis’s proposed generic ZORYVE cream. Arcutis said it planned to file suit and defend its patents; litigation and generic-entry timing remain uncertain.
Key investor verification points
- Confirm whether Arcutis met the $31.0 million financing covenant by April 1, 2024, and whether any default, waiver, amendment, or debt acceleration followed.
- Track cash burn, product revenue and collections, payer access—including Medicare and Medicaid—and the spending required to support commercialization.
- Assess the sustainability and net economics of ZORYVE sales, including rebates, discounts, royalties, and the reported $11.6 million accrued sales deductions at year-end.
- Verify FDA decisions and timing for the atopic dermatitis and scalp/body psoriasis applications, and monitor the clinical progress and funding needs of ARQ-255, ARQ-252, and ARQ-234.
- Follow the Padagis ANDA litigation, patent defenses, and potential generic competition; the filing states that ZORYVE-related U.S. patents generally extend into 2037, with a seborrheic-dermatitis foam method patent to 2041.
- Review dilution and financing capacity, including the ATM program, outstanding pre-funded warrants, and the substantial debt-service obligations.